Dual-targeting liposomes with active recognition of GLUT5 and αvβ3 for triple-negative breast cancer

Pu, Yanchi; Zhang, Hao; Yao, Peng; Fu, Qiuyi; Yue, Qiming; Zhao, Yi; Guo, Li; Wu, Yong

doi:10.1016/j.ejmech.2019.111720

Cited by 45 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 Liposomes comodified by fructose and RGD targeting transporter, such as GLUT5 and integrin a v bβ3, were reported to have enhanced anti-proliferative abilities and efficient accumulation at the tumor site of triple-negative breast cancer. 56 In the present study, both prepared liposomes encapsulated PTX with a high encapsulation efficiency over 92% and displayed suitable particle diameter and surface charge parameters, which are thought to be directly related to the endocytosis process. [57][58][59] The in vitro cellular uptake of Lip2N was investigated in the BxPC-3 human PDAC cell line by confocal laser scanning microscopy and flow cytometry, and the intracellular delivery efficiency of Lip2N was superior to that of unmodified liposome (Figure 2, P=0.069), which is similar to our previous study.…”

Section: Discussionmentioning

confidence: 50%

<p>Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer</p>

Yang¹,

Wang²,

Luo

et al. 2020

DDDT

View full text Add to dashboard Cite

Introduction: Pancreatic cancer, or pancreatic duct adenocarcinoma (PDAC), remains one of the most lethal cancers and features insidious onset, highly aggressive behavior and early distant metastasis. The dense fibrotic stroma surrounding tumor cells is thought to be a shield to resist the permeation of chemotherapy drugs in the treatment of PDAC. Thus, we synthesized a pancreas-targeting paclitaxel-loaded PEGylated liposome and investigated its antitumor efficacy in the patient-derived orthotopic xenograft (PDOX) nude mouse models of PDAC. Methods: The PTX-loaded PEGylated liposomes were prepared by film dispersionultrasonic method and modified by an N,N-dimethyl tertiary amino residue. Morphology characteristics of the PTX-loaded liposomes were observed by transmission electron microscope (TEM). The PDOX models of PDAC were established by orthotopic implantation and imaged by a micro positron emission tomography/computed tomography (PET/CT) imaging system. The in vivo distribution and antitumor study were then carried out to observe the pancreas-targeting accumulation and the antitumor efficacy of the proposed PTX liposomes. Results: PTX loaded well into both modified (PTX-Lip2N) and unmodified (PTX-Lip) PEGylated liposomes with spherical shapes and suitable parameters for the endocytosis process. The PDOX nude mouse models were successfully created in which high 18 F-FDG intaking regions were observed by micro-PET/CT. In addition to higher cellular uptakes of PTX-Lip2N by the BxPC-3 cells, the proposed nanoparticle had a notable penetrating ability towards PDAC tumor tissues, and consequently, the antitumor ability of PTX-Lip2N was significantly superior to the unmodified PTX-Lip in vivo PDOX models and even more effective than nab-PTX in restraining tumor growth. Conclusion: The modified pancreas-targeting PTX-loaded PEGylated liposomes provide a promising platform for the treatment of pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 50%

<p>Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer</p>

Yang¹,

Wang²,

Luo

et al. 2020

DDDT

View full text Add to dashboard Cite

show abstract

“…Even after 24 h, the modified liposomes present in the cancer cells were significantly greater compared to the remaining groups ( Figure 3 ). Thus, researchers studied the environment of the tumor and designed a therapeutic regimen that reduced the undesired effect on normal cells while improving targeting ability ( Pu et al, 2019 ).…”

Section: Rgd Engineered Liposomes As Arsenal Against Carcinomamentioning

confidence: 99%

Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer

Sheikh

Alhakamy

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a life-threatening disease, contributing approximately 9.4 million deaths worldwide. To address this challenge, scientific researchers have investigated molecules that could act as speed-breakers for cancer. As an abiotic drug delivery system, liposomes can hold both hydrophilic and lipophilic drugs, which promote a controlled release, accumulate in the tumor microenvironment, and achieve elongated half-life with an enhanced safety profile. To further improve the safety and impair the off-target effect, the surface of liposomes could be modified in a way that is easily identified by cancer cells, promotes uptake, and facilitates angiogenesis. Integrins are overexpressed on cancer cells, which upon activation promote downstream cell signaling and eventually activate specific pathways, promoting cell growth, proliferation, and migration. RGD peptides are easily recognized by integrin over expressed cells. Just like a multistage rocket, ligand anchored liposomes can be selectively recognized by target cells, accumulate at the specific site, and finally, release the drug in a specific and desired way. This review highlights the role of integrin in cancer development, so gain more insights into the phenomenon of tumor initiation and survival. Since RGD is recognized by the integrin family, the fate of RGD has been demonstrated after its binding with the acceptor’s family. The role of RGD based liposomes in targeting various cancer cells is also highlighted in the paper.

show abstract

“…The liposome contained fructose and RGD peptides to recognize GLUT5 and αvβ3 actively. The dual functionalized liposome loaded with PTX showed elevated growth inhibition of MDA-MB-231 and 4T1 cells [ 134 ].…”

Section: Dual Targeting Liposomal Drug Deliverymentioning

confidence: 99%

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Pandian

Vijayakumar

Murugesan³

et al. 2022

Heliyon

View full text Add to dashboard Cite

Dual-targeting liposomes with active recognition of GLUT5 and αvβ3 for triple-negative breast cancer

Cited by 45 publications

References 48 publications

<p>Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer</p>

<p>Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer</p>

Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Contact Info

Product

Resources

About